Ultra-rare sarcomas collectively account for roughly 20% of all soft tissue and bone sarcomas, highlighting that they affect a large number of patients.
Ultra-rare sarcomas warrant dedicated clinical attention; extends rationale for inclusive research and guideline prioritization.
Altogether, the incidence of ultra-rare sarcomas accounts for roughly 20% of all soft tissue and bone sarcomas. This confirms that the challenges inherent in ultra-rare sarcomas affect large numbers of patients.
No takes yet. Share an insight, caveat, or question.
Stacchiotti et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: